Summary.-CEA immune complexes and free CEA were determined in 363 patients with histologically confirmed adenocarcinoma of the gastrointestinal tract before surgery and in a post-operative follow-up. Circulating CEA immune complexes (CEA-IC) could be detected preoperatively in 89 patients. Incidence of CEA-IC increased with increasing tumour extension; 72/89 patients with CEA-IC showed already metastatic disease progression, 40/89 had nonresectable tumours. Patients with preoperative CEA-IC had a poorer prognosis than patients without CEA-IC but with high levels of free CEA, or CEA-negative patients. The appearance of CEA-IC with consecutive increases in the postoperative follow-up indicated disease recurrence. In 32/55 relapse cases, circulating CEA-IC were detected postoperatively, all 32 cases developing metastatic spread of disease.
ANTIBODIES reacting with carcinoembryonic antigen (CEA) have originally been demonstrated in patients with nonmetastatic digestive-system cancers and in pregnant women by Gold (1967) using an indirect haemagglutination technique. After the development of highly sensitive radioimmunoassay methods the existence of circulating anti-CEA antibodies could be confirmed (Gold et al., 1972; McSween, 1975) . Evidence for the presence of CEA immune complexes (CEA-IC) in glomerular deposits has been given for a case of colonic carcinoma with nephrotic syndrome (Costanza et al., 1973) as well as for a case of pancreatic carcinoma where a complex containing immunoglobulin M and a CEA cross-reacting component could be isolated from the ascitic fluid (Harvey et al., 1978) . Recently, it was also shown that the sera of patients with gastrointestinal (GI) cancer contained a fraction of CEA-IC in which CEA was bound to IgM and partly also to IgG, and which could be separated from the free CEA. The binding of CEA to IgM and IgG was demonstrated by displacement experiments with a radioactive CEA marker using radioimmunodiffusion. Free CEA-binding immunoglobulins could not be detected (Kapsopoulou-Dominos & Anderer, 1979a) .
In the last decade there was controversy about the autoantigenicity of CEA. Various groups using different techniques were unable to confirm the existence of circulating anti-CEA antibodies (Collatz et al., 1971; LoGerfo et al., 1972; Sorokin et al., 1973) . One group, however, could demonstrate circulating antibodies against NCA (nonspecific cross-reacting antigen), a glycoprotein present in normal human tissue and strongly cross-reacting with CEA by means of a "common site" antibody (Von Kleist et al., 1972 . The authors stressed the point that anti-CEA antibodies might be specific antibodies against NCA.
Antibodies, specific for CEA or NCA, in the presence of antigen excess should be found predominantly in the fraction of immune complexes. The detection of CEA immune complexes in sera of patients with gastrointestinal cancer (KapsopoulouDominos & Anderer, 1979a) provokes the question whether these complexes may block tumour-cell destruction by immune lymphocytes, thus enhancing tumour growth. Evidence that "blocking antibodies" are antigen-antibody complexes has been given by several groups (Sjogren et al., 1971; Baldwin et al., 1972; Jose & Seshadri, 1974) .
In our present study, performed in the years 1976 to 1979, we examined the possible correlation of preoperative CEA-IC with the degree of tumour extension, the postoperative changes of the amount of CEA bound to immunoglobulins during a 3-year follow-up study and the survival rate of patients with CEA-IC. We used a routine determination of CEA bound to immunoglobulins (Kapsopoulou-Dominos & Anderer 1979b) which is based on the fact that immune complexes are precipitated together with the bulk of other serum proteins when perchloric acid is added to the serum. CEA present in the perchloric acid precipitates was found to be bound to IgM and IgG, which could be demonstrated in radioimmunological displacement experiments. The amount of CEA corresponded fairly well to that obtained by column fractionation (KapsopoulouDominos & Anderer, 1979a,b (1978) . Sera were obtained from blood samples taken a few days before and 8-10 days after operation, and thereafter at intervals of 2-3 months.
Radioimmunoassay.-The concentration of free CEA in the sera was determined after perchloric acid extraction by the Hansen Z-gel method (Hansen et al., 1971 ) using the CEA-Roche RIA test kit (Roche Diagnostics, Basel, Switzerland). Variations in the anti-CEA serum batches of the CEA Roche RIA test kit were controlled on the basis of our own internal CEA standards.
The CEA-IC were found exclusively in the perchloric-acid precipitate (KapsopoulouDominos& Anderer, 1979b) provided that dilution of the original serum (0.5 ml + 2 ml saline) addition of perchloric acid and sedimentation of the resulting precipitate (2500 g, 20 min) was carried out without delay. After removal of the perchloric-acid extracts the amount of CEA bound in immune complexes was determined in the perchloric-acid sediment as follows: The wall of the test tube containing the sediment obtained from 0 5 ml of original serum, wras gently rinsed with 5 ml H20 without perturbing the sediment. The supernatant fluid was decanted and the sediment dissolved in 2ml 2M Tris solution yielding about pH 9-5. Thereafter, an aliquot of 0 5 ml was brought to 5 ml by adding saline and dialysed against O-O1M ammonium acetate (pH 6 8) followed by determination of CEA with the Roche RIA test without further perchloric-acid treatment. The sensitivity of the approach for the determination of CEA-IC was mainly limited by the criteria of the CEA Roche-RIA test. The lower limit for reproducible determinations of CEA in the perchloric-acid sediment was found to be 3.5 ng/ml original serum.
Optimal separation of free CEA and CEA-IC by perchloric-acid precipitation was dependent on the overall protein concentration of the serum. Sera with a high level of free CEA were prediluted with an adequate control serum before precipitation of the CEA-IC with perchloric acid, since predilution with buffer alone yielded a decreased amount of perchloric-acid precipitate, and also a decreased amount of CEA-IC in the precipitates, possibly due to formation of acidsoluble complexes (Kapsopoulou-Dominos & Anderer, 1979b) . Control sera contained no "27 CEA-IC and were generally obtained from healthy persons.
Perchloric-acid precipitation of the CEA-IC together with the bulk of serum proteins includes the risk of unspecific co-precipitation and inclusion of free CEA in the precipitate. In a separate study this possibility was investigated, using undiluted sera which contained various concentrations of exogenous CEA and radioiodinated CEA (1 ng) as a marker. The amount of free CEA in the perchloric-acid precipitates varied between 3 and 10% at all CEA concentrations between 30 and 1000 ng CEA/ml serum. These findings gave the basis for a correction of the amount of CEA bound in immune complexes present in perchloric acid precipitates.
In our control sera the intra-assay variance (1 a) for the determination of free CEA was 4-8 + 0 4 ng/ml serum and of complex bound CEA 4.5 + 1-3 ng/ml serum.
RESULTS

Incidence of preoperative CEA immune complexes
Circulating CEA-IC were detected in 89 of 363 patients with histologically proven adenocarcinoma of the GI tract. All of these 89 patients also had a high serum concentration of free CEA, except 13 with a free CEA level less than 2 ng/ml serum. In Fig. 1 Survival of patients with preoperative CEA-IC All of our 363 patients now have a follow-up of free CEA and CEA-IC for at least 2 years, and some for more than 3 years. A comparison of the survival of patients after surgery yields more detailed information on the prognosis of these patients. We selected 3 subgroups specified by the following preoperative CEA criteria: (1) patients with CEA-IC; (2) patients with high levels of free CEA but with no detectable circulating CEA-IC; (3) CEA-patients. The survival curves in Fig. 2A show that patients with stomach cancer and preoperative CEA-IC have a poor prognosis, with a half life of about 120 days after surgery, compared with patients with only high levels of free CEA (half life 300 days) and patients with neither high free CEA nor CEA-IC (600 days), The survival curves of patientp with colorectpl cancer (Fig. 2B) In thegroup of 158 patients with curative resections we have had up to date 57 cases of disease recurrence with consecutively increasing levels of free CEA. CEA-IC were detected in the sera of 34/57 patients up to 9 months before clinical diagnosis was possible (4/17 patients with primary resection of stomach cancer, 29/39 with primary colorectal cancer, 1/1 with pancreatic cancer). All 9 patients with local recurrence had no detectable circulating CEA-IC (5 patients with stomach cancer, 4 with colorectal cancer). Patients with detectable CEA-IC always had distant metastatic spread. In Fig. 3 the time course of free CEA and CEA-IC is given for a case with a resected primary carcinoma of the rectum and second-look surgery for a local recurrence. The patient had no CEA-IC until 30 months after the second-look operation, when the patient developed a peritoneal carcinosis. It is noteworthy that the time course of CEA-IC in cases with recurrent disease did not always parallel the course of free CEA. In 7/32 cases of disease recurrence and detectable CEA-IC the amount of complex-bound CEA was distinctly higher than the amount of free CEA, 2-6 months before clinical diagnosis, partly immediately after primary resection (2 stomach cancer, 5 colorectal cancer). We also found intermediate increases of CEA-IC up to 2 months after surgery, not necessarily linked to a simultaneous increase of free CEA, which were usually found in cases with lymphnode metastasis. Sometimes, similar intermediate increases later in the follow-up could also be detected, for instance, in 9 cases with resected primary carcinomas of the stomach and rectum and a temporary infection of the urological tract.
In the course of our study, 100 patients with far-advanced tumour growth could be followed up to death by serial determinations of CEA-IC and free CEA. In this group 510% of the patients had Baldwin & Embleton, 1974; Steele et al., 1975; Zoller et al., 1976; Tagliabue et al., 1979 ). An alternative explanation resides in the possibility that the formation of CEA-IC is a result of cross-reacting antibodies. However, autoantibodies against NCA (Collatz et al., 1971; Von Kleist & Burtin, 1966) seem not to be involved, since increases in the concentration of NCA are of less clinical value in indicating tumour progression than those of CEA (Von Kleist et al., 1977) . This would most likely also apply to NCA immune complexes. On the other hand NCA-specific antibodies should preferably bind to NCA which is present in a manyfold excess in the serum as compared to CEA (Von Kleist et al., 1977) and according to the expected affinity of these antibodies all free NCA should be bound in complexes before CEA complexes are formed.
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